PSTX vs. STRO, ADAP, IVVD, GLUE, MGX, SOPH, CHRS, CADL, JSPR, and AGEN
Should you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Invivyd (IVVD), Monte Rosa Therapeutics (GLUE), Metagenomi (MGX), SOPHiA GENETICS (SOPH), Coherus BioSciences (CHRS), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
Sutro Biopharma (NASDAQ:STRO) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
Sutro Biopharma received 90 more outperform votes than Poseida Therapeutics when rated by MarketBeat users. Likewise, 64.74% of users gave Sutro Biopharma an outperform vote while only 64.71% of users gave Poseida Therapeutics an outperform vote.
Sutro Biopharma has higher revenue and earnings than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.
97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are owned by institutional investors. 6.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 2.1% of Poseida Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sutro Biopharma has a net margin of -74.61% compared to Sutro Biopharma's net margin of -131.95%. Poseida Therapeutics' return on equity of -94.18% beat Sutro Biopharma's return on equity.
Sutro Biopharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
Sutro Biopharma presently has a consensus price target of $12.50, indicating a potential upside of 211.72%. Poseida Therapeutics has a consensus price target of $14.67, indicating a potential upside of 359.77%. Given Sutro Biopharma's higher possible upside, analysts plainly believe Poseida Therapeutics is more favorable than Sutro Biopharma.
In the previous week, Sutro Biopharma had 15 more articles in the media than Poseida Therapeutics. MarketBeat recorded 21 mentions for Sutro Biopharma and 6 mentions for Poseida Therapeutics. Sutro Biopharma's average media sentiment score of 0.56 beat Poseida Therapeutics' score of 0.02 indicating that Poseida Therapeutics is being referred to more favorably in the news media.
Summary
Sutro Biopharma beats Poseida Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Poseida Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poseida Therapeutics Competitors List
Related Companies and Tools
